-
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
-
M.
Mrugala
(2009)
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Neurology, 72 8
-
(2012)
Phase III Trial of Bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: Final progression-free survival and interim overall survival results in Avaglio
-
M.
Cohen,
Y.
Shen,
P.
Keegan,
R.
Pazdur
(2009)
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
The oncologist, 14 11
-
Onkar
Singh,
Shilpi
Gupta,
P.
Baghel,
S.
Shukla,
D.
Paramhans,
R.
Mathur
(2010)
Esophageal carcinoma in a 16-year-old girl 8 years after gastrotomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 1
-
R.
Soffietti,
E.
Trevisan,
R.
Rudà,
L.
Bertero,
C.
Bosa,
M.
Fabrini,
I.
Lolli
(2011)
Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
V.
Levin,
L.
Bidaut,
P.
Hou,
Ashok
Kumar,
J.
Wefel,
B.
Bekele,
Jai
Grewal,
S.
Prabhu,
M.
Loghin,
M.
Gilbert,
E.
Jackson
(2011)
Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.
International journal of radiation oncology, biology, physics, 79 5
-
R.
Zuniga,
R.
Torcuator,
R.
Jain,
Joseph
Anderson,
Thomas
Doyle,
S.
Ellika,
L.
Schultz,
T.
Mikkelsen
(2009)
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
Journal of Neuro-Oncology, 91
-
A.
Sturdza,
B.
Millar,
N.
Bana,
N.
Laperriere,
G.
Pond,
R.
Wong,
A.
Bezjak
(2008)
The use and toxicity of steroids in the management of patients with brain metastases
Supportive Care in Cancer, 16
-
D.
Mould,
K.
Sweeney
(2007)
The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.
Current opinion in drug discovery & development, 10 1
-
J.
Vredenburgh,
A.
Desjardins,
J.
Herndon,
J.
Marcello,
D.
Reardon,
J.
Quinn,
J.
Rich,
S.
Sathornsumetee,
S.
Gururangan,
J.
Sampson,
Melissa
Wagner,
L.
Bailey,
D.
Bigner,
A.
Friedman,
H.
Friedman
(2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 30
-
J.
Vredenburgh,
A.
Desjardins,
J.
Kirkpatrick,
D.
Reardon,
K.
Peters,
J.
Herndon,
J.
Marcello,
L.
Bailey,
S.
Threatt,
J.
Sampson,
A.
Friedman,
H.
Friedman
(2012)
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
International journal of radiation oncology, biology, physics, 82 1
-
D.
Reardon,
A.
Desjardins,
K.
Peters,
S.
Gururangan,
J.
Sampson,
R.
McLendon,
J.
Herndon,
A.
Bulusu,
S.
Threatt,
A.
Friedman,
J.
Vredenburgh,
H.
Friedman
(2012)
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
Journal of Neuro-Oncology, 107
-
D.
Reardon,
A.
Desjardins,
J.
Vredenburgh,
S.
Gururangan,
J.
Sampson,
S.
Sathornsumetee,
R.
McLendon,
J.
Herndon,
J.
Marcello,
J.
Norfleet,
A.
Friedman,
D.
Bigner,
H.
Friedman
(2009)
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
British Journal of Cancer, 101
-
J.
Vredenburgh,
A.
Desjardins,
J.
Herndon,
J.
Dowell,
D.
Reardon,
J.
Quinn,
J.
Rich,
S.
Sathornsumetee,
S.
Gururangan,
Melissa
Wagner,
D.
Bigner,
A.
Friedman,
H.
Friedman
(2007)
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Clinical Cancer Research, 13
-
R.
Stupp,
Warren
Mason,
M.
Bent,
M.
Weller,
B.
Fisher,
M.
Taphoorn,
K.
Bélanger,
A.
Brandes,
C.
Marosi,
U.
Bogdahn,
J.
Curschmann,
Robert
Janzer,
Samuel
Ludwin,
T.
Gorlia,
A.
Allgeier,
D.
Lacombe,
J.
Cairncross,
E.
Eisenhauer,
R.
Mirimanoff
(2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
The New England journal of medicine, 352 10
-
T.
Kreisl,
L.
Kim,
K.
Moore,
P.
Duic,
C.
Royce,
I.
Stroud,
Nancy
Garren,
M.
Mackey,
J.
Butman,
K.
Camphausen,
John
Park,
P.
Albert,
H.
Fine
(2009)
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 5
-
V.
Levin,
L.
Bidaut,
P.
Hou,
Ashok
Kumar,
J.
Wefel,
B.
Bekele,
Jai
Grewal,
S.
Prabhu,
M.
Loghin,
M.
Gilbert,
E.
Jackson
(2012)
Erratum: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system (International Journal of Radiation Oncology Biology Physics (2011) 79:5 (1487-95) DOI: 10.1016/j.ijrobp.2009.12.061)
International Journal of Radiation Oncology Biology Physics, 84
-
H.
Poulsen,
K.
Grunnet,
M.
Sorensen,
P.
Olsen,
B.
Hasselbalch,
K.
Nelausen,
M.
Kosteljanetz,
U.
Lassen
(2009)
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
Acta Oncologica, 48
-
Michael
Michael,
M.
Doherty
(2005)
Tumoral drug metabolism: overview and its implications for cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 1
-
M.
Nagane,
R.
Nishikawa,
Y.
Narita,
Hiroyuki
Kobayashi,
S.
Takano,
N.
Shinoura,
T.
Aoki,
K.
Sugiyama,
J.
Kuratsu,
Y.
Muragaki,
Y.
Sawamura,
M.
Matsutani
(2012)
Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma†
Japanese Journal of Clinical Oncology, 42
-
M.
Gil,
R.
Peñas,
G.
Reynés,
C.
Balañà,
P.
Pérez-Segura,
A.
García-Velasco,
C.
Mesía,
O.
Gallego,
C.
Fernández-Chacón,
M.
Martínez-García,
A.
Herrero,
R.
Andrés,
M.
Benavides,
T.
Quintanar,
X.
Pérez-Martin
(2012)
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)
Anti-Cancer Drugs, 23
-
A.
Norden,
G.
Young,
K.
Setayesh,
A.
Muzikansky,
R.
Klufas,
G.
Ross,
A.
Ciampa,
L.
Ebbeling,
B.
Levy,
J.
Drappatz,
S.
Kesari,
P.
Wen
(2008)
Bevacizumab for recurrent malignant gliomas
Neurology, 70
-
W.
Yung,
R.
Albright,
J.
Olson,
R.
Fredericks,
K.
Fink,
M.
Prados,
M.
Brada,
A.
Spence,
R.
Hohl,
W.
Shapiro,
M.
Glantz,
H.
Greenberg,
R.
Selker,
N.
Vick,
R.
Rampling,
H.
Friedman,
P.
Phillips,
J.
Bruner,
N.
Yue,
D.
Osoba,
S.
Zaknoen,
V.
Levin
(2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
British Journal of Cancer, 83
-
J.
Vredenburgh,
T.
Cloughesy,
M.
Samant,
M.
Prados,
P.
Wen,
T.
Mikkelsen,
D.
Schiff,
L.
Abrey,
W.
Yung,
N.
Paleologos,
M.
Nicholas,
R.
Jensen,
A.
Das,
H.
Friedman
(2010)
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
The oncologist, 15 12
-
(2012)
Do we know the optimal bevacizumab dose in recurrent malignant glioma ( MG ) ? The experience of the Spanish Group GEINO with bevacizumab 5 mg / kg
-
S.
Sathornsumetee,
A.
Desjardins,
J.
Vredenburgh,
R.
McLendon,
J.
Marcello,
J.
Herndon,
A.
Mathe,
M.
Hamilton,
J.
Rich,
J.
Norfleet,
S.
Gururangan,
H.
Friedman,
D.
Reardon
(2010)
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Neuro-oncology, 12 12
-
R.
Jain,
D.
Duda,
Jeffrey
Clark,
J.
Loeffler
(2006)
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Nature Clinical Practice Oncology, 3
-
A.
Lai,
A.
Tran,
P.
Nghiemphu,
W.
Pope,
O.
Solis,
M.
Selch,
Emese
Filka,
W.
Yong,
P.
Mischel,
L.
Liau,
S.
Phuphanich,
K.
Black,
S.
Peak,
R.
Green,
C.
Spier,
T.
Kolevska,
J.
Polikoff,
L.
Fehrenbacher,
R.
Elashoff,
T.
Cloughesy
(2011)
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 2
-
Louis
N,
Ohgaki
H,
Cavenee
K
(1982)
The classification of tumours of the central nervous system.
Neuropathology and applied neurobiology, 8 1
-
B.
Escudier,
A.
Płużańska,
P.
Koralewski,
A.
Ravaud,
S.
Bracarda,
C.
Szczylik,
C.
Chevreau,
Marek
Filipek,
B.
Melichar,
E.
Bajetta,
V.
Gorbunova,
J.
Bay,
I.
Bodrogi,
A.
Jagiełło-Gruszfeld,
N.
Moore
(2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
The Lancet, 370
-
H.
Dvorak
(2002)
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 21
-
M.
Furuse,
S.
Miyatake,
Tomo
Miyata,
Erina
Yoritsune,
S.
Kawabata,
T.
Kuroiwa,
M.
Karajannis,
M.
Fisher,
S.
Milla,
K.
Cohen,
G.
Legault,
J.
Wisoff,
D.
Harter,
E.
Hartnett,
Amanda
Merkelson,
M.
Bloom,
G.
Dhall,
David
Jones,
A.
Korshunov,
S.
Pfister,
C.
Eberhart,
D.
Zagzag,
J.
Allen,
O.
Chinot,
W.
Wick,
W.
Mason,
R.
Henriksson,
F.
Saran,
R.
Nishikawa,
M.
Hilton,
L.
Abrey,
T.
Cloughesy,
K.
Field,
J.
Simes,
A.
Nowak,
E.
Hovey,
H.
Wheeler,
L.
Cher,
Christopher
Brown,
A.
Livingstone,
K.
Sawkins,
M.
Rosenthal,
Cabaret
Investigators,
Heather
McCrea,
K.
Kesavabhotla,
J.
Boockvar,
L.
Kleinberg,
J.
Blakeley,
T.
Mikkelsen,
G.
Stevens,
X.
Ye,
S.
Ryu,
S.
Desideri,
B.
Desai,
V.
Giranda,
S.
Grossman,
M.
Badruddoja,
Marjorie
Pazzi,
B.
Stea,
P.
Lefferts,
N.
Contreras,
K.
Wallen,
Rajul
Shah,
N.
Rance,
Kurt
Schroeder,
A.
Sanan,
C.
Kut,
S.
Raza,
Wenxuan
Liang,
Ameer
Abutaleb,
Jiefeng
Xi,
Jessica
Mavadia,
H.
Guerrero-Cázares,
E.
McVeigh,
Xingde
Li,
A.
Quiñones‐Hinojosa,
A.
Sloan,
J.
Reese,
L.
Rogers,
Heather
Embree,
H.
Lazarus,
H.
Fung,
Dona
Kane,
B.
Dropulić,
S.
Gerson,
Gabriele
Tsung,
S.
Green,
A.
Lai,
R.
Green,
Emese
Filka,
T.
Cloughesy,
P.
Nghiemphu,
R.
Saito,
Y.
Yamashita,
Y.
Sonoda,
Masayuki
Kanamori,
T.
Kumabe,
T.
Tominaga,
A.
Mohammadi,
S.
Chao,
D.
Peereboom,
G.
Barnett,
J.
Suh,
C.
Brewer,
M.
Vogelbaum,
A.
Desjardins,
K.
Peters,
J.
Herndon,
L.
Bailey,
L.
Alderson,
T.
Ranjan,
J.
Sampson,
A.
Friedman,
D.
Bigner,
H.
Friedman,
J.
Vredenburgh,
T.
Kaley,
E.
Pentsova,
A.
Omuro,
I.
Mellinghoff,
C.
Nolan,
I.
Gavrilovic,
L.
Deangelis,
E.
Holland,
M.
Lacouture,
E.
Ludwig,
A.
Lassman,
K.
Shih,
J.
Bacha,
Dennis
Brown,
W.
Garner,
R.
Schwartz,
H.
Burris,
P.
Rosenblatt,
S.
Chowdhary,
A.
Weir,
G.
Shepard,
M.
Shastry,
P.
Griner,
J.
Hainsworth,
C.
Nock,
A.
Kerstetter,
J.
Supko,
J.
Barnholtz-Sloan,
Robert
Miller,
J.
Rich,
N.
Takebe,
M.
Prados
(2012)
CLIN-ONGOING CLINICAL TRIALS
Neuro-oncology, 14
-
J.
Folkman
(1971)
Tumor angiogenesis: therapeutic implications.
The New England journal of medicine, 285 21
-
Jianfeng
Lu,
R.
Bruno,
S.
Eppler,
W.
Novotny,
B.
Lum,
J.
Gaudreault
(2008)
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Cancer Chemotherapy and Pharmacology, 62
-
Clinical pharmacokinetics of bevacizumab (Avastin®) following every 2-or 3-week dosing.
-
D.
Hanahan,
J.
Folkman
(1996)
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
Cell, 86
-
D.
Hicklin,
L.
Ellis
(2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 5
-
R.
Stupp,
M.
Hegi,
W.
Mason,
M.
Bent,
M.
Taphoorn,
R.
Janzer,
S.
Ludwin,
A.
Allgeier,
B.
Fisher,
K.
Bélanger,
P.
Hau,
A.
Brandes,
J.
Gijtenbeek,
C.
Marosi,
C.
Vecht,
K.
Mokhtari,
P.
Wesseling,
S.
Villà,
E.
Eisenhauer,
T.
Gorlia,
M.
Weller,
D.
Lacombe,
J.
Cairncross,
R.
Mirimanoff
(2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
The Lancet. Oncology, 10 5
-
K.
Miller,
Molin
Wang,
J.
Gralow,
M.
Dickler,
M.
Cobleigh,
E.
Perez,
T.
Shenkier,
D.
Cella,
N.
Davidson
(2007)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
The New England journal of medicine, 357 26
-
T.
Cloughesy,
J.
Vredenburgh,
B.
Day,
A.
Das,
H.
Friedman
(2010)
Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study.
Journal of Clinical Oncology, 28
-
P.
Nghiemphu,
W.
Liu,
Yohan
Lee,
T.
Than,
C.
Graham,
A.
Lai,
Richard
Green,
W.
Pope,
L.
Liau,
P.
Mischel,
S.
Nelson,
R.
Elashoff,
T.
Cloughesy
(2009)
Bevacizumab and chemotherapy for recurrent glioblastoma
Neurology, 72
-
European Medicines Agency: Avastin (bevacizumab) product page
-
S.
Guiu,
S.
Taillibert,
O.
Chinot,
L.
Taillandier,
J.
Honnorat,
P.
Dietrich,
J.
Maire,
J.
Guillamo,
B.
Guiu,
I.
Catry-Thomas,
F.
Capelle,
A.
Thiebaut,
S.
Cartalat-Carel,
C.
Deville,
P.
Fumoleau,
A.
Desjardins,
K.
Xuan,
B.
Chauffert
(2008)
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
Revue neurologique, 164 6-7
-
W.
Pope,
Q.
Xia,
V.
Paton,
A.
Das,
J.
Hambleton,
Hyun
Kim,
J.
Huo,
Matthew
Brown,
Jonathan
Goldin,
T.
Cloughesy
(2011)
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
Neurology, 76
-
O.
Chinot,
T.
Rouge,
Nicola
Moore,
A.
Zeaiter,
Asha
Das,
Heidi
Phillips,
Z.
Modrušan,
T.
Cloughesy
(2011)
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
Advances in Therapy, 28
-
S.
Gururangan,
S.
Chi,
T.
Poussaint,
A.
Onar-Thomas,
R.
Gilbertson,
S.
Vajapeyam,
H.
Friedman,
R.
Packer,
B.
Rood,
J.
Boyett,
L.
Kun
(2010)
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 18
-
J.
Folkman
(1971)
Transplacental carcinogenesis by stilbestrol.
The New England journal of medicine, 285 7
-
Eric
Wong,
K.
Hess,
M.
Gleason,
K.
Jaeckle,
A.
Kyritsis,
M.
Prados,
V.
Levin,
W.
Yung
(1999)
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 8
-
J.
Wefel,
T.
Cloughesy,
J.
Zazzali,
M.
Zheng,
M.
Prados,
P.
Wen,
T.
Mikkelsen,
D.
Schiff,
L.
Abrey,
W.
Yung,
N.
Paleologos,
M.
Nicholas,
R.
Jensen,
J.
Vredenburgh,
A.
Das,
H.
Friedman
(2011)
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
Neuro-oncology, 13 6
-
Joost
Verhoeff,
Cristina
Lavini,
Myra
Linde,
L.J.A.
Stalpers,
Charles
Majoie,
Jaap
Reijneveld,
R.
Wouter,
van
Furth,
Dick
Richel
(2009)
UvA-DARE ( Digital Academic Repository ) Angiogenesis inhibition in high grade glioma Verhoeff
-
Yvonne
Lin,
C.
Nguyen,
Jose
Mendoza,
E.
Escandón,
D.
Fei,
Y.
Meng,
N.
Modi
(1999)
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
The Journal of pharmacology and experimental therapeutics, 288 1
-
K.
Margolin,
M.
Gordon,
E.
Holmgren,
J.
Gaudreault,
W.
Novotny,
G.
Fyfe,
D.
Adelman,
Susan
Stalter,
J.
Breed
(2001)
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 3
-
A.
Desjardins,
D.
Reardon,
J.
Herndon,
J.
Marcello,
J.
Quinn,
J.
Rich,
S.
Sathornsumetee,
S.
Gururangan,
J.
Sampson,
L.
Bailey,
D.
Bigner,
A.
Friedman,
H.
Friedman,
J.
Vredenburgh
(2008)
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Clinical Cancer Research, 14
-
A.
Sandler,
R.
Gray,
M.
Perry,
J.
Brahmer,
J.
Schiller,
A.
Dowlati,
R.
Lilenbaum,
David
Johnson
(2006)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
The New England journal of medicine, 355 24
-
M.
Gordon,
K.
Margolin,
M.
Talpaz,
G.
Sledge,
E.
Holmgren,
R.
Benjamin,
Susan
Stalter,
S.
Shak,
D.
Adelman
(2001)
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 3
-
T.
Perren,
A.
Swart,
J.
Pfisterer,
J.
Ledermann,
E.
Pujade-Lauraine,
G.
Kristensen,
M.
Carey,
P.
Beale,
A.
Cervantes,
C.
Kurzeder,
A.
Bois,
J.
Sehouli,
R.
Kimmig,
A.
Stähle,
F.
Collinson,
S.
Essapen,
C.
Gourley,
A.
Lortholary,
F.
Selle,
M.
Mirza,
A.
Leminen,
M.
Plante,
D.
Stark,
W.
Qian,
M.
Parmar,
A.
Oza
(2011)
A phase 3 trial of bevacizumab in ovarian cancer.
The New England journal of medicine, 365 26
-
H.
Friedman,
M.
Prados,
P.
Wen,
T.
Mikkelsen,
D.
Schiff,
L.
Abrey,
W.
Yung,
N.
Paleologos,
M.
Nicholas,
R.
Jensen,
J.
Vredenburgh,
Jane
Huang,
M.
Zheng,
T.
Cloughesy
(2009)
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
-
S.
Raval,
S.
Hwang,
L.
Dorsett
(2007)
Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
Journal of Clinical Oncology, 25
-
J.
Gaudreault,
R.
Bruno,
F.
Kabbinavar,
A.
Sing,
David
Johnson,
J.
Lu
(2004)
Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
-
B.
Hasselbalch,
U.
Lassen,
S.
Hansen,
M.
Holmberg,
M.
Sorensen,
M.
Kosteljanetz,
H.
Broholm,
M.
Stockhausen,
H.
Poulsen
(2010)
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Neuro-oncology, 12 5
-
P.
Wen,
D.
MacDonald,
D.
Reardon,
T.
Cloughesy,
A.
Sorensen,
E.
Galanis,
J.
Degroot,
W.
Wick,
M.
Gilbert,
A.
Lassman,
C.
Tsien,
T.
Mikkelsen,
Eric
Wong,
M.
Chamberlain,
R.
Stupp,
K.
Lamborn,
M.
Vogelbaum,
M.
Bent,
Susan
Chang
(2010)
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 11
-
R.
Jain,
E.
Tomaso,
D.
Duda,
J.
Loeffler,
A.
Sorensen,
T.
Batchelor
(2007)
Angiogenesis in brain tumours
Nature Reviews Neuroscience, 8
-
A.
Young,
B.
Sahakian,
T.
Robbins,
P.
Cowen
(1999)
The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers
Psychopharmacology, 145
-
D.
Reardon,
J.
Vredenburgh,
A.
Desjardins,
K.
Peters,
A.
Coan,
J.
Herndon,
H.
Friedman
(2011)
Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma.
-
D.
Louis,
H.
Ohgaki,
O.
Wiestler,
W.
Cavenee,
P.
Burger,
A.
Jouvet,
B.
Scheithauer,
P.
Kleihues
(2007)
The 2007 WHO Classification of Tumours of the Central Nervous System
Acta Neuropathologica, 114
-
J.
Folkman
(1990)
What is the evidence that tumors are angiogenesis dependent?
Journal of the National Cancer Institute, 82 1
-
Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.
-
H.
Hurwitz,
L.
Fehrenbacher,
W.
Novotny,
T.
Cartwright,
J.
Hainsworth,
W.
Heim,
J.
Berlin,
A.
Baron,
S.
Griffing,
E.
Holmgren,
N.
Ferrara,
G.
Fyfe,
B.
Rogers,
R.
Ross,
F.
Kabbinavar
(2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
The New England journal of medicine, 350 23
-
P.
Nghiemphu,
R.
Green,
W.
Pope,
A.
Lai,
T.
Cloughesy
(2008)
Safety of anticoagulation use and bevacizumab in patients with glioma.
Neuro-oncology, 10 3
-
D.
Levêque,
S.
Wisniewski,
F.
Jehl
(2005)
Pharmacokinetics of therapeutic monoclonal antibodies used in oncology.
Anticancer research, 25 3c
-
W.
Wick,
V.
Puduvalli,
M.
Chamberlain,
M.
Bent,
A.
Carpentier,
L.
Cher,
W.
Mason,
M.
Weller,
Shengyan
Hong,
L.
Musib,
A.
Liepa,
D.
Thornton,
H.
Fine
(2010)
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
-
P.
Gutin,
F.
Iwamoto,
K.
Beal,
N.
Mohile,
S.
Karimi,
B.
Hou,
S.
Lymberis,
Y.
Yamada,
Jenghwa
Chang,
L.
Abrey
(2009)
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
International journal of radiation oncology, biology, physics, 75 1
-
H.
Steiner,
Sybille
Karcher,
M.
Mueller,
E.
Nalbantis,
S.
Kunze,
C.
Herold‐Mende
(2004)
Autocrine Pathways of the Vascular Endothelial Growth Factor (VEGF) in Glioblastoma Multiforme: Clinical Relevance of Radiation-Induced Increase of VEGF Levels
Journal of Neuro-Oncology, 66
